Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection

Posted on August 7, 2015 by Edward J. Gane, Robert H. Hyland, Di An, Evguenia Svarovskaia, Phillip S. Pang, Diana Brainard, Catherine A. Stedman

We performed a phase 2 clinical trial to evaluate the efficacy and safety of ledipasvir and sofosbuvir, with or without ribavirin, in patients infected with HCV genotype 3 or 6.

This entry was posted in News. Bookmark the permalink.